S M Stemmer
Overview
Explore the profile of S M Stemmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1137
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jhaveri K, Eli L, Wildiers H, Hurvitz S, Guerrero-Zotano A, Unni N, et al.
Ann Oncol
. 2023 Aug;
34(10):885-898.
PMID: 37597578
Background: HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib +...
2.
Zer A, Icht O, Yosef L, Avram D, Jacobi O, Fenig E, et al.
Ann Oncol
. 2022 Mar;
33(7):720-727.
PMID: 35339649
Background: Classical Kaposi sarcoma (cKS) is a rare human herpesvirus 8-associated sarcoma with limited treatment options. We evaluated the efficacy and safety of nivolumab in combination with ipilimumab in patients...
3.
Deutsch O, Haviv Y, Krief G, Keshet N, Westreich R, Stemmer S, et al.
Sci Rep
. 2020 Dec;
10(1):21995.
PMID: 33319845
The 80% mortality rate of pancreatic-cancer (PC) makes early diagnosis a challenge. Oral fluids (OF) may be considered the ultimate body fluid for non-invasive examinations. We have developed techniques to...
4.
Rugo H, Andre F, Yamashita T, Cerda H, Toledano I, Stemmer S, et al.
Ann Oncol
. 2020 May;
31(8):1001-1010.
PMID: 32416251
Background: Alpelisib (α-selective phosphatidylinositol 3-kinase inhibitor) plus fulvestrant is approved in multiple countries for men and postmenopausal women with PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast...
5.
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, et al.
Ann Oncol
. 2019 Aug;
30(11):1842.
PMID: 31407010
No abstract available.
6.
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, et al.
Ann Oncol
. 2018 May;
29(7):1541-1547.
PMID: 29718092
Background: The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone...
7.
Perl G, Nordheimer S, Lando S, Benedict C, Brenner B, Perry S, et al.
BMC Cancer
. 2016 Aug;
16:630.
PMID: 27519697
Background: Recent epidemiological studies indicate the rate of gastrointestinal (GI) malignancies among younger patients is increasing, mainly due to colorectal cancer. There is a paucity of data regarding the magnitude...
8.
Ben-Aharon I, Abir R, Perl G, Stein J, Gilad G, Toledano H, et al.
BMC Cancer
. 2016 Aug;
16:620.
PMID: 27506811
Background: Current evidence indicates sub-optimal incidence of fertility preservation (FP) in eligible patients. We present herein our designated multidisciplinary program for FP in pediatric and adolescent population and present our...
9.
10.
Abir R, Ben-Aharon I, Garor R, Yaniv I, Ash S, Stemmer S, et al.
Hum Reprod
. 2016 Feb;
31(4):750-62.
PMID: 26848188
Study Question: Is a protocol that combines in vitro maturation of germinal vesicle-stage oocytes and their vitrification with freezing of cortical ovarian tissue feasible for use in fertility preservation for...